Imaging for Immunotherapy Studies
Unprecedented Number of Clinical Trials
Immunotherapy treatment mobilizes the body’s adaptive immune system to fight cancer. There are currently an unprecedented number of new investigational agents within immuno-oncology (I-O) in clinical development and clinical trial testing.
BioTel Research has a unique depth of experience in the implementation of immune-related oncology response criteria.
27
studies
707
study sites
4043
subjects
Response Criteria Expertise
Our experience with specific immune-related criteria includes studies in various phases of development (pre-clinical through phase 3) in multiple indications. BioTel Research scientists were involved in the early phases of the design of these criteria, having presented on the development of the irRECIST/iRECIST criteria at numerous industry and scientific meetings beginning in 2015.
Scientists and Software for Every Image
The majority of these studies employ a dual reader with adjudication read paradigm, utilizing both in-house and contracted readers. BTR currently has software implementations of all major immune-related oncology response criteria active within the company core laboratory, including irRC, irRECIST, and iRECIST. Our flexibility and in-house scientific expertise have allowed us to implement these criteria both as published and with sponsor-specific modifications.
GENERAL INQUIRIES:
Toll-Free: 1.877.267.3324
Local: 1.301.214.7600
Fax: 1.301.214.7601
BTRinfo@gobio.com
BUSINESS DEVELOPMENT:
Local: 1.301.214.7628
BTRbusiness@gobio.com
CLINICAL TRIALS SUPPORT:
Toll Free: 1.877.324.8326
BTRsupport@gobio.com
MID-ATLANTIC:
One Preserve Parkway
Suite 600
Rockville, MD 20852
USA
NORTHEAST:
155 Corporate Woods
Suite 180
Rochester, NY 14623
USA
WEST COAST:
400 Oyster Point Blvd
Suite 339
South San Francisco, CA 94080
USA
EUROPE:
Building 3 Chiswick Park
Suite 258
566 Chiswick High Road
London, W4 5YA
UK
Connect with Us for the latest on our clinical trials services, including medical imaging and cardiac safety testing